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Abstract: Depression has a major impact on social functioning. Decreased concentration, 
mental and physical slowing, loss of energy, lassitude, tiredness, and reduced self-care are 
all symptoms related to reduced noradrenergic activity. Depressed mood; loss of interest or 
pleasure; sleep disturbances; and feelings of worthlessness, pessimism, and anxiety are related 
to reduced activity of both serotonergic and noradrenergic neurotransmission. The importance 
of noradrenergic neurotransmission in social functioning is supported by studies with the spe-
cific norepinephrine reuptake inhibitor reboxetine. In healthy volunteers, reboxetine increases 
cooperative social behavior and social drive. A placebo-controlled study in depressed patients 
comparing reboxetine with the selective serotonin reuptake inhibitor (SSRI) fluoxetine showed 
significantly greater improvement in social adaptation with reboxetine. Two recent studies have 
examined the effect of the serotonin and norepinephrine reuptake inhibitor milnacipran on 
social adaptation. A study in depressed patients found that at the end of 8 weeks of treatment 
with milnacipran, 42.2% patients were in remission on the Social Adaptation Self-evaluation 
Scale (SASS). Another study in depressed workers or homemakers found that mean depression 
scores were significantly reduced after 2 weeks, whereas the SASS scores were significantly 
improved after 4 weeks. A preliminary study comparing depressed patients treated with 
  milnacipran or the SSRI paroxetine showed that milnacipran treatment resulted in a greater 
number of patients in social remission. The available data thus suggest that milnacipran may 
improve social functioning, with a possibly greater effect than the SSRI paroxetine. These 
preliminary data suggest further evaluation of social dysfunction and its treatment outcome in 
future trials of milnacipran.
Keywords: social functioning, Social Adaptation Self-evaluation Scale (SASS), depression, 
noradrenergic neurotransmission, serotonin and norepinephrine reuptake inhibitors (SNRIs), 
milnacipran
Introduction
The widespread disturbances of monoamine neurotransmission that occur in   depression 
are probably fundamental to its pathophysiology.1,2 More specifically, a deficiency in 
serotonin (5-HT), norepinephrine (NE), and possibly dopamine (DA)   neurotransmission 
has been suggested.3,4 A relationship exists between the different neurotransmitter 
deficits and the symptoms of major depression.5 Depressed mood; loss of interest or 
pleasure; sleep disturbances; and feeling of worthlessness, pessimism, and anxiety are 
symptoms related to changes in both 5-HT and NE neurotransmission.5,6   Agitation, 
loss of appetite, decreased libido, suicidal ideation, aggressive behavior (verbal or 
physical), and irritability are symptoms related principally to the dysfunction of 5-HT Neuropsychiatric Disease and Treatment 2011:7(Suppl 1) submit your manuscript | www.dovepress.com
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neurotransmission.5,6 DA is important in the regulation of 
drive.7,8 Reduced   noradrenergic activity is responsible for 
decreased concentration, mental and physical slowing, loss 
of energy, lassitude, tiredness, and reduced self-care.5,6
Noradrenergic symptom cluster 
and social dysfunction
The symptoms that are thought to be principally due to a defi-
cit in noradrenergic transmission, the so-called noradrenergic 
symptom cluster, are those that result in social dysfunction 
(Figure 1). “Social dysfunction” is a collective term used 
to describe a variety of emotional problems experienced 
in social situations. It frequently leads to family disruption 
and social isolation. In the workplace it can lead to absen-
teeism and “presenteeism” (a term used to describe the lost 
productivity a worker experiences when he or she is able to 
attend work but is not performing optimally.9 Depression has 
a major negative impact on social functioning,10–14 which is 
possibly one of the most important factors affecting quality 
of life in depressed patients.
In the International Classification of Diseases, 10th 
Revision (ICD-10) and Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition (DSM-IV) diagnostic criteria 
of major depression, the item “lack of interests or pleasure” 
only partly covers the concept of decreased social ability. 
However, in addition to the simple presence of certain 
symptoms, DSM-IV requires that the symptoms should cause 
significant distress or impairment in social, occupational, or 
other important areas of functioning.15
Improvement of social dysfunction 
during antidepressant treatment
Increasingly, the enhancement of social functioning is 
considered to be an important therapeutic target in the treat-
ment of depression.15,16 Full recovery from depression thus 
requires not only the resolution of classical symptoms but 
also an improvement in the interaction of the individual 
with his or her environment.10,11,13 The ability to improve 
social functioning should legitimately influence the choice 
of antidepressant therapy.12
The measurement of social adaptation should therefore 
be an integral part of the assessment of the outcome of 
depressive episodes. A number of instruments have been 
developed to measure social functioning, each with certain 
advantages and disadvantages.17 Although several self- or 
clinician-evaluated social adjustment scales are available, 
they are frequently complex and time consuming, and their 
conceptual background is often poorly defined.18–20 The 
three most frequently used instruments for measuring social 
functioning are the 36-item Short-Form Health Survey,21 
the Social   Adjustment Scale Self-report,22 and the more 
recently developed Social Adaptation Self-evaluation 
Scale (SASS).18 It has been suggested17 that the SASS might 
be the most appropriate for studies exploring hypotheses 
about   mechanisms involved in social dysfunction.
The importance of NE neurotransmission in social func-
tioning is supported by studies using the specific NE reuptake 
inhibitor reboxetine. The effects of reboxetine have been 
studied in healthy volunteers using a stranger-dyadic social 
interaction paradigm and cooperative game situations,22–24 
where it was found to increase cooperative social behavior 
and social drive, making participants more self-confident 
and assertive. In contrast, the selective serotonin reuptake 
inhibitor (SSRI) citalopram had significantly less effect on 
cooperative behavior.22
Because depression causes extensive social dysfunc-
tion, antidepressant treatment would be expected to lead 
to improved social functioning. An early study25 found 
that social and interpersonal maladjustments occurring in 
depressed women improved with antidepressant treatment 
during 8-month follow-up. The considerable improvement 
in social adjustment, however, occurred more slowly than 
for other symptoms. Symptomatic relapse was accompanied 
by rapid social worsening.25
The first double-blind, placebo-controlled study to use 
the SASS showed that 8 weeks of treatment with reboxetine 
(8 mg/d) resulted in a significantly greater improvement in 
social functioning compared with patients treated with the 
SSRI fluoxetine (20 mg/d) or with placebo (Figure 2).26,27 
Another study28 comparing the effects of reboxetine 
(8–10 mg/d) and fluoxetine (20–40 mg/d) over 8 weeks 
found that both antidepressants improved the scores on the 
  Hamilton Depression Rating Scale (HDRS) to a similar 
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Figure 1 The noradrenergic symptom cluster and social dysfunction. The components 
of  the  noradrenergic  symptom  cluster  are  closely  linked  to  social  dysfunction. 
“Presenteeism” is a term used to describe the lost productivity a worker experiences 
when he or she is able to attend work but is not performing optimally.Neuropsychiatric Disease and Treatment 2011:7 (Suppl 1) submit your manuscript | www.dovepress.com
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Figure 2 Improvement in Social Adaptation Self-evaluation Scale (SASS) score during antidepressant therapy. 
Drawn from data in references 27 and 28.
Abbreviations: NRI, norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
extent. In patients who achieved remission from their depres-
sive symptoms, however, social dysfunction was improved 
to a significantly greater extent by patients taking reboxetine 
compared with fluoxetine (Figure 2).
These studies suggest that antidepressants with an impor-
tant noradrenergic component, such as reboxetine, may be 
particularly effective in improving social functioning.29 If 
improved social adaptation is related to increased NE activ-
ity, then serotonin and norepinephrine reuptake inhibitors 
(SNRIs) should be particularly effective in reducing social 
dysfunction in depressed patients.
There have been relatively few studies of SNRIs investi-
gating their effects on social adaptation. A small study30 that 
compared treatment of depressed patients with venlafaxine 
and amitriptyline found the two drugs to be equally effec-
tive in relieving depressive symptoms. Venlafaxine-treated 
patients showed a significantly greater improvement in social 
adjustment. An open-label case study of five patients with 
treatment-resistant severe depression31 found that treatment 
with high-dose (450–600 mg/d) venlafaxine resulted in an 
improvement in depressive symptoms (.50% decrease in 
baseline HDRS scores) in four patients. Social adjustment 
scores of two of these patients were normalized by the end of 
the study. An open-label study of 26 patients suffering from 
seasonal affective disorder (SAD)32 treated with duloxetine 
(60–120 mg/d) for 8 weeks showed that both SAD and social 
adaptation were improved. The studies with milnacipran are 
discussed at the end of the next section.
Milnacipran: the most 
noradrenergic SNRI
Of the four SNRIs currently available, milnacipran is the most 
noradrenergic in terms of its selectivity for the inhibition of the 
reuptake of NE and 5-HT (Figure 3).33,34 There is neurochemi-
cal and neurophysiological evidence that   milnacipran acts 
by increasing NE neurotransmission. A study investigating 
the influence of NE transporter polymorphism (NET-T182C 
polymorphism) on the antidepressant effect of milnacipran35 
found a significant difference (P , 0.03) in response, depend-
ing on the genotype of the patients (T/T 76.7% responders; 
T/C 57.8% responders; C/C 20%   responders). Similarly, 
antidepressant response with milnacipran was sensitive to 
NET-G1287A polymorphism, with the A/A genotype being 
associated with a slower onset of therapeutic response.35 
Venlafaxine
Duloxetine
Milnacipran
Desvenlafaxine
NE 5-HT
5-HT NE
Figure  3  Visual  representation  of  the  selectivity  for  serotonin  (5-HT)  and 
norepinephrine (NE) transporter in vitro. The light gray segments represent the 
relative affinity for the 5-HT transporter, and the dark gray segments represent the 
relative affinity for the NE transporter. 
Calculated from data in reference 33.Neuropsychiatric Disease and Treatment 2011:7(Suppl 1) submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
24
Kasper et al
In contrast, there was no influence of 5-HTT polymorphisms 
on the antidepressant response to milnacipran.35 These results 
suggest that the effect of   milnacipran on the NE transporter 
is fundamental to its action.
The effects of milnacipran 
on the noradrenergic 
symptom cluster
Concentration
The effect of milnacipran has been specifically studied 
on certain symptoms of the noradrenergic symptom 
cluster. The critical flicker fusion (CFF) task38 evaluates 
the   integrative capacity of the brain and the ability to 
discriminate discrete quanta of sensory information. The 
CFF is sensitive to psychoactive drugs, and a decrease in 
CFF threshold indicates decreased cognitive capacity. In a 
study of elderly (.65 years) healthy volunteers in whom 
amitriptyline (50 mg/d for 3 days) significantly decreased 
CFF,   milnacipran (75 mg/d for 3 days) caused a small but 
significant increase in CFF, indicating a small enhancement 
of cognitive capacity.39
Retardation
The HDRS defines “retardation” in item 8 as slowness 
of thought and speech, impaired ability to concentrate, 
and decreased motor activity, and rates it on a 0–4 scale. 
A subanalysis of data from a study comparing milnacipran 
(100 mg/d) with paroxetine (20 mg/d)40 examined item 8 
of the HDRS in comparison with response on the Clinical 
Global Improvement (CGI) scale. Patients with low levels 
of retardation (score 0 or 1) had similar response rates on 
milnacipran and paroxetine. Patients with high levels of 
retardation (score 3 or 4), however, responded significantly 
better to milnacipran than to paroxetine (Figure 4).
Tiredness
Milnacipran has not been investigated extensively in sleep 
disorders, but in various studies milnacipran has been noted to 
improve disturbed sleep patterns by decreasing sleep latency 
and nocturnal awakenings and increasing the latency of rapid 
eye movement sleep.39–42 This improvement in sleep is likely 
to go some way to improving tiredness.
The effects of milnacipran  
on social dysfunction
Two recent studies have examined the effect of milnacip-
ran on social adaptation as measured by the SASS. Both 
have been published exclusively in Japanese but have been 
  presented and discussed in detail in a recent review.43
In one study,44 milnacipran was administered at 50 mg/d, 
increasing to 100 mg/d (mean final dose 83.7 mg/d) to 
45 patients with major depressive disorder for 8 weeks. 
  Significant improvement in the classical symptoms of depres-
sion, as measured by HDRS and Beck Depression Inventory 
(BDI), was observed after 2 weeks, and significant improve-
ment of social dysfunction (SASS) after 4 weeks (Figure 5). 
After 8 weeks of treatment, 51.1% patients were in remission 
for depression (HDRS , 7) and 42.2% for social dysfunction 
(SASS . 35). Nonresponders on the HDRS had no significant 
improvement in their SASS score at endpoint. There was 
a significant negative correlation (P , 0.01) between the 
reduction in HDRS score from baseline to endpoint and the 
increase in SASS score from baseline to endpoint.
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0 or 1
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*
Figure 4 Antidepressant response and the degree of psychomotor retardation. 
Retardation score is the score on item 8 of the Hamilton Depression Rating Scale. 
Drawn from data in reference 38.
Note: * P  ,  0.05  compared  with  paroxetine-treated  patients  with  retardation 
scores of 3 or 4.
Abbreviation: CGI, Clinical Global Improvement.
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Figure 5 Evolution of depression and social function during milnacipran treatment. 
Depression ratings (black lozenges and line) are the mean Hamilton Depression 
Rating Scale (HDRS 17 ) scores (± standard error of the mean). Social function ratings 
are the mean Social Adaptation Self-evaluation Scale (SASS) scores (± standard error 
of the mean).
Drawn from data in reference 44.
Note: * P  ,  0.01  compared  with  respective  baseline  values;  n  =  101  used  for 
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The second study45 included 113 patients, employees, or 
homemakers with major depressive episodes. Milnacipran 
was administered at 25–50 mg/d, increasing to 100 mg/d 
by 2 weeks, and then continuing at this dose for 8 weeks 
(average final dose 85.4 mg/d). Mean HDRS and Zung 
Self-rating Depression Scale (SDS) scores were signifi-
cantly reduced (P , 0.01) from 2 weeks, whereas the SASS 
was only significantly increased (P , 0.01) from 4 weeks. 
At   endpoint, 67.4% patients were classified as responders 
($50% reduction of baseline HDRS), and 43.0% were in 
remission (HDRS # 7); 33.3% patients had remission on 
SASS ($35 points). There was a significant negative cor-
relation between ∆SASS (baseline to endpoint difference) 
and ∆HDRS (-0.39 P , 0.01), although the correlation was 
considerably weaker than between the two depression scales 
(∆HDRS and ∆SDS; 0.74 P , 0.01).
Both studies showed significant improvement on the 
SASS scale from 4 weeks of treatment, whereas a significant 
improvement on depression scales occurred by 2 weeks. Both 
studies reported a significant negative correlation between 
changes in the SASS and changes in the HDRS. This correla-
tion was, however, weaker than that between two depression 
rating scales. Globally, these data suggest that improvement 
in social function, as measured by the SASS, may be more 
difficult and slower to achieve than improvement in classical 
depressive symptoms.
A recent review of the effect of SNRIs on social 
  function43 mentions an unpublished study that compares the 
  improvement of social function in depressed patients treated 
with milnacipran (mean dose 83 mg/d) and paroxetine (mean 
dose 35 mg/d). Milnacipran treatment resulted in a greater 
number of patients with social remission than treatment with 
paroxetine.
Conclusion
The symptoms that constitute the noradrenergic symptom 
cluster are those that play an important role in social dys-
function. There is a suggestion that antidepressants activat-
ing NE neurotransmission may improve social functioning 
more rapidly and/or to a greater extent than those acting 
exclusively on 5-HT function.43 The efficacy of reboxetine 
in the recovery of social function compared with SSRIs is 
compatible with the importance of noradrenergic deficit in 
social dysfunction. If this is indeed true, SNRIs would also 
be expected to be particularly effective in improving social 
functioning.
Milnacipran is the most noradrenergic SNRI in terms of 
its selectivity for the NE transporter and 5-HT transporter. 
It has been shown to have positive effects on concentration 
and retardation. This latter effect has been shown to be 
  significantly greater than with paroxetine. Among the SNRIs, 
milnacipran might therefore be expected to be particularly 
effective in reducing social dysfunction associated with 
depression. Evidence, which is still incomplete, suggests 
that milnacipran may improve social function in depressed 
patients. Although the effects on depressive symptoms 
and social dysfunction are correlated, improvement in 
social function appears to have a slower time course than 
  improvement of other depressive symptoms.
The studies that are currently available are all small, and 
many of them are not comparative. This is a clear limita-
tion of support for the hypothesis. Although there is a first 
indication that milnacipran may possibly produce a greater 
improvement of social function than paroxetine, the ques-
tion is still open. Clearly, the studies need to be replicated 
in a controlled and comparative environment. In addition, 
the interesting question of the potential positive interaction 
between psychotherapy and pharmacotherapy in the improve-
ment of social function needs to be addressed.
Social dysfunction is one of the most important factors 
affecting quality of life of depressed patients, and it is pos-
sibly of even greater importance in the treatment of elderly 
patients suffering from major depression. For the patient to 
recover fully from the effects of depression, it is important 
to have not only full and sustained relief from the classical 
symptoms of depression but also a complete recovery of the 
ability to interact with friends and other individuals in the 
family and work environment. The enhancement of social 
functioning should thus be considered a major therapeutic 
goal in the management of depression.
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